Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 6, 2007, Pages 601-608

  Gauthier, Kathryn M ^a   Yang, Wenqi ^a   Gross, Garrett J ^a   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Arachidonic acid; Cytochrome P450; EDHF; Endothelium; Ischemia; Platelets; Potassium channels; Reperfusion

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); EPOXYICOSATRIENOIC ACID;

BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CONDITIONING; CORONARY ARTERY BLOOD FLOW; DNA POLYMORPHISM; DOG; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; FATTY ACID METABOLISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACID; BLOOD VESSELS; CARDIOVASCULAR SYSTEM; EICOSANOIC ACIDS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 36349001971     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318159cbe3     Document Type: Review

References (86)

1. Lin J, Kobari Y, Zhu Z, et al. Human umbilical vein endothelial cells express P450 2C8 mRNA: Cloning of endothelial P450 epoxygenase. Endothelium. 1996;4:219-229.
2. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-497.
3. Node K, Ruan XL, Dai J, et al. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001;276:15983-15989.
4. DeLozier TC, Kissling GE, Coulter SJ, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Met Dispos. 2007;35:682-688.
5. Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997;272:12551-12559.
6. Wu S, Moomaw CR, Tomer KB, et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996;271:3460-3468.
7. Elbekai RH, El-Kadi AOS. Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol Ther. 2006;112:564-587.
8. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;276:36059-36062.
9. Capdevila JH, Falck JR. Biochemical and molecular characteristics of the cytochrome P450 arachidonic acid monooxygenase. Prostaglandins Other Lipid Mediat. 2000;623:271-292.
10. Daikh BE, Lasker JM, Raucy JL, et al. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther. 1994;271:1427-1433.
11. Zeldin DC, Dubois, RN, Falck JR, et al. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic epoxygenase isoform. Arch Biochem Biophys. 1995;322:76-86.
12. Falck JR, Krishna UM, Reddy YK, et al. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol. 2003;284:H337-H349.
13. Campbell WB, Holmes BB, Falck JR, et al. Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol. 2006;290:H64-H71.
14. Zou AP, Fleming JT, Falck JR, et al. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(+)-channel activity. Am J Physiol Renal Physiol. 1996;270:F822-F832.
15. Zhang Y, Oltman CL, Lu T, et al. EET homologs potently dilate coronary microvessels and activate BKCa channels. Am J Physiol Heart Circ Physiol. 2001;280:H2430-H2440.
16. Zeldin DC, Kobayashi J, Falck JR, et al. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem. 1993;268:6402-6407.
17. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol. 2007;292:C996-C1012.
18. Zhu Y, Schieber EB, McGiff JC, et al. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension. 1995;25:854-859.
19. Karara A, Dishman E, Falck JR, et al. Endogenous epoxyeicosatrienoyl- phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem. 1991;266:7561-7569.
20. Fang X, Kaduce TL, Weintraub NL, et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem. 2001;276:14867-14874.
21. Fang X, Weintraub NL, McCaw RB, et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol. 2004;287:H2412-H2420.
22. Oltman CL, Weintraub NL, VanRollins M, et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res. 1998;83:932-939.
23. Weintraub NL, Fang X, Kaduce TL, et al. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 1997;81:258-267.
24. Ca channels. Am J Physiol Heart Circ Physiol. 2002;282:H1656-H1664.
25. Imig JD, Navar LG, Roman RJ, et al. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol. 1996;7:2364-2370.
26. Fang X, Weintraub NL, Oltman CL, et al. Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol. 2002;283:H2306-H2314.
27. Fang X, VanRollins M, Kaduce TL, et al. Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. J Lipid Res. 1995;36:1236-1246.
28. Pinto A, Abraham NG, Mullane KM. Arachidonic acid-induced endothelial-dependent relaxation of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther. 1987;240:856-863.
29. Campbell WB, Gebremehdin D, Pratt FP, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived relaxing factors. Circ Res. 1996;78:415-423.
30. Hecker M, Bara AT, Bauersachs J, et al. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 1994;481:407-414.
31. Fulton D, McGiff JC, Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol. 1992;107:722-725.
32. + channels. Circulation. 2001;103:1992-1998.
33. Fisslthaler B, Popp R, Michaelis UR, et al. Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase. Hypertension. 2001;38:1427-1432.
34. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1979;30:293-331.
35. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265-9269.
36. Cowen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation. 1995;92:3337-3349.
37. Campbell WB, Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome p450 metabolites of arachidonic acid in the regulation of tone. Circ Res. 1999;84:484-488.
38. Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
39. Chauhan SD, Nilsson H, Ahluwalia A, et al. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA. 2003;100:1426-1431.
40. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521-1530.
41. Campbell WB, Spitzbarth N, Gauthier KM, et al. 11,12,15- Trihydroxyeicosatrienoic acid mediates ACh-induced relaxations in rabbit aorta. Am J Physiol Heart Circ Physiol. 2003;285:H2648-H2656.
42. Campbell WB, Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol Hypertens. 2002;11:177-183.
43. Campbell WB, Holmes BB, Falck JR, et al. Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol. 2006;290:H64-H71.
44. Ca channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006;290:H491-H499.
45. Gebremedhin D, Harder DR, Pratt PF, et al. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: Role of a cytochrome P450 metabolite. J Vasc Res. 1998;35:274-284.
46. Popp R, Bauersachs J, Hecker M, et al. A transferable, beta-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J Physiol. 1996;497:699-709.
47. Gauthier KM, Edwards EM, Falck JR, et al. 14,15-epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension. 2005;45:666-671.
48. Rosolowsky M, Campbell WB. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol Heart Circ Physiol. 1993;264:H327-H335.
49. Pratt PF, Li P, Hillard CJ, et al. Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs. Am J Physiol Heart Circ Physiol. 2001;280:H1113-H1121.
50. Li PL, Campbell WB. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 1997;80:877-884.
51. Fukao M, Mason HS, Kenyon JL, et al. Regulation of BK(Ca) channels expressed in human embryonic kidney 293 cells by epoxyeicosatrienoic acid. Mol Pharmacol. 2001;59:16-23.
52. Li PL, Chen CL, Bortell R, et al. 11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ Res. 1999;85:349-356.
53. Li PL, Zhang DX, Ge Z-D, et al. Role of ADP-ribose in 11,12-EET-induced activation of KCa channels in coronary arterial smooth muscle cells. Am J Physiol Heart Circ Physiol. 2002;282:H1229-H1236.
54. ATP channels by 11,12-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol. 2005;288:H358-H364.
55. Weston AH, Feletou M, Vanhoutte PM, et al. Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol. 2005;145:775-784.
56. 2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res. 2005;97:908-915.
57. Fitzpatrick FA, Ennis MD, Baze ME, et al. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem. 1986;261:15334-15338.
58. Krotz F, Riexinger T, Buerkle MA, et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol. 2004;24:595-600.
59. Dhanasekaran A, Al-Saghir R, Lopez B, et al. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol. 2006;291:H517-H531.
60. Yang S, Lin L, Chen JX, et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol. 2007;293:H142-H151.
61. Liu Y, Zhang Y, Schmelzer K, et al. The antiinflammatory effect of laminar flow: The role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. PNAS. 2005;102:16747-16752.
62. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;20:1276-1279.
63. Falck JR, Reddy LM, Reddy YK, et al. 11,12-Epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-α-induced VCAM-1 expression. Bioorg Med Chem. 2003;13:4011-4014.
64. Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive channels and p42/p44-MAPK pathway. Circ Res. 2004;95:506-514.
65. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006;99:442-450.
66. Nithipatikom K, Moore JM, Isbell MA, et al. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;291:H537-H542.
67. Gross GJ, Hsu A, Falck JR, et al. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol. 2007;42:687-691.
68. Granville DJ, Tashakkor B, Takeuchi C, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci. 2004;101:1321-1326.
69. Moffat MP, Ward CA, Bend J, et al. Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes. Am J Physiol Heart Circ Physiol. 1993;264:H1154-H1160.
70. Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004;110:2132-2136.
71. Lee CR, North KE, Bray MS, et al. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics. 2007;17:349-358.
72. Fornage M, Boerwinkle E, Doris PA, et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the coronary artery risk development in young adults (CARDIA) study. Circulation. 2004;109:335-339.
73. Lee CR, North KE, Bray MS, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Hum Mol Genet. 2006;15:1640-1649.
74. Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003;13:715-720.
75. ATP channels in rats are activated in rats by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol. 2006;575:627-644.
76. Lu T, VanRollins M, Lee HC. Stereospecific activation of cardiac ATPsensitive channels by epoxyeicosatrienoic acids: a structural determinant study. Mol Pharmacol. 2002;62:1076-1082.
77. ATP channel activation by epoxyeicosatrienoic acids. J Biol Chem. 2005;280:119097-119104.
78. Gauthier KM, Deeter C, Krishna UM, et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: A selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002;90:1028-1036.
79. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol-3-kinase/Akt cell survival pathway. J Biol Chem. 1998;273:19929-19932.
80. Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res. 2002;90:377-379.
81. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res. 2001;88:802-809.
82. Gauthier KM, Falck JR, Reddy LM, et al. 14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol Res. 2004;49:515-524.
83. Yang W, Holmes BB, Raj Gopal V, et al. Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther. 2007;321:1023-1031.
84. Wong PY, Lin KT, Yan YT, et al. 14(R),15(S)- epoxyeicosatrienoic acid (14(R),15(S)-EET) receptor in guinea pig mononuclear cell membranes. J Lipid Mediat. 1993;6:199-208.
85. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690.
86. Spiecker M, Liao JK. Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc Med. 2006;16:204-208.